Valbenazine

Phase 1Withdrawn

2 views this week 0 watching💤 Quiet

Interest: 18/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tardive Dyskinesia

Conditions

Tardive Dyskinesia

Trial Timeline

Oct 18, 2024 → Oct 18, 2025

NCT ID

NCT05053321

About Valbenazine

Valbenazine is a phase 1 stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05053321. Target conditions include Tardive Dyskinesia.

What happened to similar drugs?

3 of 7 similar drugs in Tardive Dyskinesia were approved

Approved (3) Terminated (1) Active (4)

🔄levetiracetam + placeboUCBPhase 3

✅Valbenazine Oral CapsuleNeurocrine BiosciencesApproved

🔄NBI-98854Neurocrine BiosciencesPhase 3

✅Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved

🔄NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3

🔄ValbenazineNeurocrine BiosciencesPhase 3

✅Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07105111	Approved	Recruiting	Aug 29, 2025	Apr 1, 2027	Schizophrenia
NCT05053321	Phase 1	Withdrawn	Oct 18, 2024	Oct 18, 2025	Tardive Dyskinesia
NCT06312189	Phase 3	Recruiting	Apr 24, 2024	Apr 1, 2026	Chorea, Huntington
NCT05859698	Approved	Completed	May 9, 2023	Dec 27, 2024	Schizophrenia
NCT04400331	Phase 3	Active	Sep 18, 2020	Mar 1, 2026	Chorea, Huntington
NCT03444038	Phase 2	Completed	Feb 8, 2018	Jul 12, 2019	Tourette Syndrome
NCT02879578	Phase 2	Completed	Jul 25, 2016	Nov 1, 2017	Tourette Syndrome
NCT02736955	Phase 3	Completed	Jun 13, 2016	Jun 30, 2017	Tardive Dyskinesia

Competing Products

13 competing products in Tardive Dyskinesia

See all competitors

Product	Company	Stage	Hype Score
Sarizotan	Merck	Pre-clinical	18
levetiracetam + placebo	UCB	Phase 3	40
Valbenazine Oral Capsule	Neurocrine Biosciences	Approved	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854	Neurocrine Biosciences	Phase 3	37
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Approved	40
NBI-98854	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 3	37
Valbenazine	Neurocrine Biosciences	Phase 3	37
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Approved	40
NBI-1065890 + Placebo	Neurocrine Biosciences	Phase 2	39